ABSTRACT: The combination of ombitasvir, dasabuvir and paritaprevir/ritonavir (referred as the 3D regimen) has proven to be associated with high sustained virologic response and optimal tolerability in hepatitis C virus-infected patients. Here we describe an HIV-HCV coinfected patient who experienced a grade 4 hyperbilirubinemia and a 2.5-fold increase in the ATV plasma trough concentrations few days after the start of 3D-based antiviral therapy who benefited from an ATV dose reduction guided by therapeutic drug monitoring.
Severe hyperbilirubinemia in an HIV-HCV coinfected patient starting the 3D regimen that resolved after TDM-guided atazanavir dose reduction / D. Cattaneo, A. Riva, E. Clementi, L. Milazzo, C. Gervasoni. - In: THERAPEUTIC DRUG MONITORING. - ISSN 0163-4356. - 38:3(2016), pp. 285-287. [10.1097/FTD.0000000000000293]
Severe hyperbilirubinemia in an HIV-HCV coinfected patient starting the 3D regimen that resolved after TDM-guided atazanavir dose reduction
D. Cattaneo
;A. Riva;E. Clementi;
2016
Abstract
ABSTRACT: The combination of ombitasvir, dasabuvir and paritaprevir/ritonavir (referred as the 3D regimen) has proven to be associated with high sustained virologic response and optimal tolerability in hepatitis C virus-infected patients. Here we describe an HIV-HCV coinfected patient who experienced a grade 4 hyperbilirubinemia and a 2.5-fold increase in the ATV plasma trough concentrations few days after the start of 3D-based antiviral therapy who benefited from an ATV dose reduction guided by therapeutic drug monitoring.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
